Brief: Hansa Biopharma Announces Restructuring Plan
05/12/2023 12:10
Dec 5 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA PLANS RESTRUCTURING TO STRENGTHEN
LONG-TERM
COMPETITIVENESS AND ADVANCE KEY DELIVERABLES
* PLANNED RESTRUCTURING WOULD RESULT IN AN APPROXIMATELY
20-25%
REDUCTION IN CURRENT WORKFORCE
* RESTRUCTURING IS SUBJECT TO NEGOTIATION WITH RELEVANT
TRADE
UNIONS
* WILL RESULT IN APPROXIMATELY 75-85 MILLION SEK IN ANNUAL
SAVINGS
WHEN IMPLEMENTED
Source text for Eikon: ID:nWkrc26Tld
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS